AU2019321432A1 - Treatment of B cell malignancies - Google Patents

Treatment of B cell malignancies Download PDF

Info

Publication number
AU2019321432A1
AU2019321432A1 AU2019321432A AU2019321432A AU2019321432A1 AU 2019321432 A1 AU2019321432 A1 AU 2019321432A1 AU 2019321432 A AU2019321432 A AU 2019321432A AU 2019321432 A AU2019321432 A AU 2019321432A AU 2019321432 A1 AU2019321432 A1 AU 2019321432A1
Authority
AU
Australia
Prior art keywords
compound
mixture
alkyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019321432A
Other languages
English (en)
Inventor
Daniel P. Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of AU2019321432A1 publication Critical patent/AU2019321432A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019321432A 2018-08-14 2019-08-13 Treatment of B cell malignancies Abandoned AU2019321432A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
AU2019321432A1 true AU2019321432A1 (en) 2021-03-25

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019321432A Abandoned AU2019321432A1 (en) 2018-08-14 2019-08-13 Treatment of B cell malignancies

Country Status (14)

Country Link
US (1) US20210299134A1 (enExample)
EP (1) EP3836935A4 (enExample)
JP (1) JP2021534115A (enExample)
KR (1) KR20210043635A (enExample)
CN (1) CN112888441A (enExample)
AU (1) AU2019321432A1 (enExample)
BR (1) BR112021002760A2 (enExample)
CA (1) CA3109184A1 (enExample)
IL (1) IL280726A (enExample)
MA (1) MA53236A (enExample)
MX (1) MX2021001606A (enExample)
SG (1) SG11202101450VA (enExample)
TW (1) TW202021591A (enExample)
WO (1) WO2020036999A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11365252B2 (en) * 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Also Published As

Publication number Publication date
JP2021534115A (ja) 2021-12-09
CA3109184A1 (en) 2020-02-20
IL280726A (en) 2021-03-25
SG11202101450VA (en) 2021-03-30
TW202021591A (zh) 2020-06-16
EP3836935A1 (en) 2021-06-23
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
MX2021001606A (es) 2021-04-19
KR20210043635A (ko) 2021-04-21
BR112021002760A2 (pt) 2021-05-11
CN112888441A (zh) 2021-06-01
WO2020036999A1 (en) 2020-02-20
MA53236A (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
CN107108637B (zh) 三唑并嘧啶化合物及其用途
JP6779870B2 (ja) 抗増殖性化合物及びその使用方法
JP2021517116A (ja) 併用療法
US11351176B2 (en) Combination therapy
CN109982687A (zh) 联合疗法
WO2020036999A1 (en) Treatment of b cell malignancies
WO2020132563A1 (en) Combination therapy
AU2019321526A1 (en) Treatment of relapsed follicular lymphoma
AU2019322858A1 (en) Combination therapy
WO2023070120A1 (en) Ketoamides for treating malignancy
CN108473504B (zh) 新型二氢吡喃并嘧啶酮衍生物及其用途
WO2020198067A1 (en) Pkm2 modulators and methods for their use

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period